Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination
In a prospective multicentre trial, the influence of schedule, compliance, age, sex and weight on the antibody response to hepatitis B vaccination was investigated. Comparison of the vaccination schedules 0, 1, 6 months (group 1; n = 143) and 0, 1, 2, 12 months (group 2; n = 141) was performed in mo...
Saved in:
Published in | European journal of clinical microbiology & infectious diseases Vol. 11; no. 4; p. 334 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
01.04.1992
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | In a prospective multicentre trial, the influence of schedule, compliance, age, sex and weight on the antibody response to hepatitis B vaccination was investigated. Comparison of the vaccination schedules 0, 1, 6 months (group 1; n = 143) and 0, 1, 2, 12 months (group 2; n = 141) was performed in months 3, 7 and 12. In addition, the antibody response was compared one month after the third and one and six months after the last vaccination. Seroprotection rates (anti-HBs greater than 10 IU/l) and antibody titres, given as geometric means (GMTs), were higher in group 1 at month 12 as well as one month after completion of three immunizations. More vaccinees of group 2, however, showed seroprotection at month 3 with higher GMTs. In addition, GMTs in group 2 were higher both one month and six months after the last vaccine dose. Determination of parallel corrected correlation factors demonstrated that age was the most important single factor, followed by body weight and sex. However, no more than 3% of the variation in the GMT can be explained by the influence of age. Due to decreased compliance with the four-dose schedule with a drop-out rate of approximately 10% of the vaccinees, the total percentage of initial vaccinees who in the end developed protective antibody levels was higher in the 0, 1, 6 months schedule. Thus, it can be concluded that subjects likely to comply will benefit from the 0, 1, 2, 12 months schedule as more rapid protection is obtained and the higher antibody levels after the booster vaccination at month 12 provide longer protection. However, vaccinees whose compliance might be questionable over a period of 12 months, should be selected for the vaccination 0, 1, 6 months schedule as compliance is at a higher level over this period and advantage can be taken of the booster effect of the third dose given in month 6. |
---|---|
AbstractList | In a prospective multicentre trial, the influence of schedule, compliance, age, sex and weight on the antibody response to hepatitis B vaccination was investigated. Comparison of the vaccination schedules 0, 1, 6 months (group 1; n = 143) and 0, 1, 2, 12 months (group 2; n = 141) was performed in months 3, 7 and 12. In addition, the antibody response was compared one month after the third and one and six months after the last vaccination. Seroprotection rates (anti-HBs greater than 10 IU/l) and antibody titres, given as geometric means (GMTs), were higher in group 1 at month 12 as well as one month after completion of three immunizations. More vaccinees of group 2, however, showed seroprotection at month 3 with higher GMTs. In addition, GMTs in group 2 were higher both one month and six months after the last vaccine dose. Determination of parallel corrected correlation factors demonstrated that age was the most important single factor, followed by body weight and sex. However, no more than 3% of the variation in the GMT can be explained by the influence of age. Due to decreased compliance with the four-dose schedule with a drop-out rate of approximately 10% of the vaccinees, the total percentage of initial vaccinees who in the end developed protective antibody levels was higher in the 0, 1, 6 months schedule. Thus, it can be concluded that subjects likely to comply will benefit from the 0, 1, 2, 12 months schedule as more rapid protection is obtained and the higher antibody levels after the booster vaccination at month 12 provide longer protection. However, vaccinees whose compliance might be questionable over a period of 12 months, should be selected for the vaccination 0, 1, 6 months schedule as compliance is at a higher level over this period and advantage can be taken of the booster effect of the third dose given in month 6. |
Author | Cseke, J Bock, H L Hingst, V Clemens, R Hess, G |
Author_xml | – sequence: 1 givenname: G surname: Hess fullname: Hess, G organization: Medical Department, University Hospital of Mainz, Germany – sequence: 2 givenname: V surname: Hingst fullname: Hingst, V – sequence: 3 givenname: J surname: Cseke fullname: Cseke, J – sequence: 4 givenname: H L surname: Bock fullname: Bock, H L – sequence: 5 givenname: R surname: Clemens fullname: Clemens, R |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/1396753$$D View this record in MEDLINE/PubMed |
BookMark | eNpNjz1PwzAURS1UVNrCwo7kPxCwnxN_jLSiUKkSC8yVaz_TVKkdxQmo_55IdGC6w706V2dOJjFFJOSes0fOmHparhk3EpgSV2TGS1EVpVBiQmbMiLIwCsQNmed8ZONYKzUlUy6MVJWYkeMmhmbA6JCmQL-tc3W0fZ0ize6AfmgwUxs9PaTc02Bdn7pMx9bGvt4nf6Yd5jbFjDSkpkk_dfyiB2xHRF9nuvxPvCXXwTYZ7y65IJ_rl4_VW7F9f92snreFAw194UUJldLc4V6BCqCdZIGVqqqYAyWNEV5b41A6Axy4Hg-8LpnEikkYvWFBHv647bA_od-1XX2y3Xl3cYZfjBNagw |
CitedBy_id | crossref_primary_10_1371_journal_pone_0133464 crossref_primary_10_1089_08828240152716556 crossref_primary_10_1111_j_1708_8305_1995_tb00661_x crossref_primary_10_1128_CVI_00539_10 crossref_primary_10_1002_jmv_27848 crossref_primary_10_1016_S0264_410X_96_00205_8 crossref_primary_10_1097_00006250_199906000_00018 crossref_primary_10_1097_AOG_0b013e3182148efe crossref_primary_10_1186_s13293_020_00304_9 crossref_primary_10_1111_j_1753_6405_2010_00496_x crossref_primary_10_1111_j_1600_0676_1996_tb00742_x crossref_primary_10_1016_0166_0934_93_90140_M crossref_primary_10_1080_14760584_2017_1338568 crossref_primary_10_1080_14760584_2023_2289566 crossref_primary_10_1136_sti_72_3_210 crossref_primary_10_2310_7060_2000_00025 crossref_primary_10_1002_bies_201200099 crossref_primary_10_1016_j_vaccine_2008_04_054 crossref_primary_10_1016_S1473_3099_10_70049_9 crossref_primary_10_1177_1010539513496136 crossref_primary_10_1586_14760584_2015_966694 crossref_primary_10_3109_00365529509089796 crossref_primary_10_1016_j_vaccine_2006_04_016 crossref_primary_10_1111_jvh_12572 crossref_primary_10_1186_s12913_017_2626_0 crossref_primary_10_1128_CMR_00084_18 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1007/BF01962073 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1435-4373 |
ExternalDocumentID | 1396753 |
Genre | Journal Article |
GroupedDBID | --- -4W -56 -5G -BR -EM -Y2 -~C .55 .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29G 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3SX 3V. 4.4 406 408 409 40D 40E 53G 5QI 5RE 5VS 67N 67Z 6NX 78A 7X7 88A 88E 8AO 8CJ 8FE 8FH 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAEOY AAFGU AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO ABAKF ABBBX ABBXA ABDZT ABECU ABELW ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBMV ACBRV ACBXY ACBYP ACDTI ACGFS ACHSB ACHVE ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACVWB ACWMK ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADMDM ADOAH ADOXG ADRFC ADTPH ADURQ ADYFF ADYPR ADZKW AEBTG AEEQQ AEFIE AEFQL AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFBBN AFEXP AFGCZ AFKRA AFLOW AFNRJ AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AI. AIAKS AIGIU AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG AOSHJ ARMRJ AXYYD AZFZN B-. BA0 BBNVY BBWZM BDATZ BENPR BGNMA BHPHI BPHCQ BVXVI CAG CCPQU CGR COF CSCUP CUY CVF D1J DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS ECM EIF EIOEI EJD EMB EMOBN EN4 EPAXT ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HCIFZ HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LK8 LLZTM M0L M1P M4Y M7P MA- MM. N2Q N9A NB0 NDZJH NPM NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TEORI TSG TSK TSV TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW VH1 W23 W48 WJK WK6 WK8 X7M YLTOR Z45 Z7U Z7W Z7X Z81 Z82 Z83 Z87 Z8O Z8Q Z8V Z91 ZGI ZMTXR ZOVNA ZXP ~EX ~KM |
ID | FETCH-LOGICAL-c282t-d3425781ceb727f28c60f047550c276993d8a9ce6c921218accd8406e50624372 |
ISSN | 0934-9723 |
IngestDate | Thu May 23 23:53:57 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c282t-d3425781ceb727f28c60f047550c276993d8a9ce6c921218accd8406e50624372 |
PMID | 1396753 |
ParticipantIDs | pubmed_primary_1396753 |
PublicationCentury | 1900 |
PublicationDate | 1992-Apr |
PublicationDateYYYYMMDD | 1992-04-01 |
PublicationDate_xml | – month: 04 year: 1992 text: 1992-Apr |
PublicationDecade | 1990 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany |
PublicationTitle | European journal of clinical microbiology & infectious diseases |
PublicationTitleAlternate | Eur J Clin Microbiol Infect Dis |
PublicationYear | 1992 |
SSID | ssj0007877 |
Score | 1.5328465 |
Snippet | In a prospective multicentre trial, the influence of schedule, compliance, age, sex and weight on the antibody response to hepatitis B vaccination was... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 334 |
SubjectTerms | Adolescent Adult Aging - immunology Body Weight Female Hepatitis B Antibodies - biosynthesis Hepatitis B Vaccines - adverse effects Hepatitis B Vaccines - immunology Humans Immunization Schedule Male Patient Compliance Prospective Studies Sex Characteristics Vaccines, Synthetic - adverse effects Vaccines, Synthetic - immunology |
Title | Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination |
URI | https://www.ncbi.nlm.nih.gov/pubmed/1396753 |
Volume | 11 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bT8IwFG5Ag-HFKGq8pw--kZmxS-kehWjQBJ4g8c2wrlUMApGhwb_kn_R07WpBiZeXhaxJAzvfvn7ncC4InYkwIJS58H7HhDoBTyIn8l3h-JRG3I2SUAhZ79zukFYvuLkNbwuFdytraZbG5-zt27qS_1gV7oFdZZXsHyxrNoUb8BnsC1ewMFx_ZePrfMKIlHwvfcYGKrZXBZcVjpAhVw2YZSGHGayTZR-ng3iczKvPKkFW9v0eDsevMmrwwGWKdTqYVhv2jisD-FrMmgLLp4HV2UnCKs_2mk3zP4OMim9xM7E9j3-P7lUNikm9bU65bglqAgeawVu6YCLRNXyelemiY49-4MhxZ-oQUswLus2RfZYWqLlmQTCweNZXEdAv_O_mWe1ALJ6rNrOAMHnKkACqF_yknxeXOnHrlSIq1qkk044MDOlDH3gvq8zPf9liJ1z9bcqopPdYcmIyMdPdQpvaC8EXClLbqMBHFVRSc0nnFbTR1hkXO-jRYAyPBbYQgQ3GMGAMS4xhjTEMqznGcI4xbDCGDcZww95xF_WuLrvNlqPnczgMHPXUSfyM8GuMx6CChUcZcYUb1MHpZV6dgPJNaD9inLAIBFKNwoYJBQHJQ5fIPpjeHlobjUd8H2EQ4omQyQkU_FsPSILEoc88AlzBPFaPDtCeel53E9WE5U4_yMNVC0eo_Am9Y7Qu4J3nJyAg0_g0M90Hgetw6A |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influence+of+vaccination+schedules+and+host+factors+on+antibody+response+following+hepatitis+B+vaccination&rft.jtitle=European+journal+of+clinical+microbiology+%26+infectious+diseases&rft.au=Hess%2C+G&rft.au=Hingst%2C+V&rft.au=Cseke%2C+J&rft.au=Bock%2C+H+L&rft.date=1992-04-01&rft.issn=0934-9723&rft.eissn=1435-4373&rft.volume=11&rft.issue=4&rft.spage=334&rft_id=info:doi/10.1007%2FBF01962073&rft_id=info%3Apmid%2F1396753&rft_id=info%3Apmid%2F1396753&rft.externalDocID=1396753 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0934-9723&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0934-9723&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0934-9723&client=summon |